There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Deciphera Pharmaceuticals (DCPH – Research Report) and Ocular Therapeutix (OCUL – Research Report) with bullish sentiments.
Deciphera Pharmaceuticals (DCPH)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Deciphera Pharmaceuticals today and set a price target of $23.00. The company’s shares closed last Friday at $12.15.
According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Deciphera Pharmaceuticals is a Strong Buy with an average price target of $42.38, a 255.8% upside from current levels. In a report issued on October 30, Piper Sandler also upgraded the stock to Buy with a $23.00 price target.
See the top stocks recommended by analysts >>
Ocular Therapeutix (OCUL)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Ocular Therapeutix today and set a price target of $12.00. The company’s shares closed last Friday at $3.26.
According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of
Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $13.40, implying a 298.8% upside from current levels. In a report issued on November 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DCPH:
- Biotech Alert: Searches spiking for these stocks today
- Deciphera price target raised to $22 from $20 at Stifel
- Deciphera price target raised to $30 from $25 at H.C. Wainwright
- Deciphera upgraded to Buy from Hold at JonesResearch
- Piper upgrades Deciphera, sees vimseltinib and Qinlock poised for upside
